異動解讀｜康方生物盤中下跌3.06%，中期業績不及預期疊加雙抗塌房爭議持續承壓

行情直擊

09/01

9月1日，康方生物盤中下跌3.06%，報87.15港元，成交額2.56億港元，延續上一交易日逾5%的跌勢。

消息面上，公司此前發布中期業績，上半年總收入18.06億元，按年增長27.92%，期內虧損4.47億元，按年收窄約24%，但仍未實現盈利，收入及毛利不及市場預期。與此同時，阿斯利康PD-1/CTLA-4雙抗臨床失敗引發市場對雙抗賽道的質疑持續發酵。儘管公司董事長夏瑜在業績會上回應稱不同企業雙抗分子結構存在本質區別，卡度尼利已有三項III期OS陽性結果，不能因單一項目失利否定整個賽道，但市場情緒短期仍偏謹慎，股價在前期累漲後持續回調。

（以上內容均基於市場公開消息，由程序或算法智能生成，僅作為股價異動提醒，不作為投資建議或交易依據。）

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/news/1108327360"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108327360\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108327360?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-01 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108327360","market":"us","top_or_hot":-1,"title":"異動解讀｜康方生物盤中下跌3.06%，中期業績不及預期疊加雙抗塌房爭議持續承壓","media":"行情直擊","content":"<p><p>9月1日，康方生物盤中下跌3.06%，報87.15港元，成交額2.56億港元，延續上一交易日逾5%的跌勢。</p><p>消息面上，公司此前發布中期業績，上半年總收入18.06億元，按年增長27.92%，期內虧損4.47億元，按年收窄約24%，但仍未實現盈利，收入及毛利不及市場預期。與此同時，阿斯利康PD-1/CTLA-4雙抗臨床失敗引發市場對雙抗賽道的質疑持續發酵。儘管公司董事長夏瑜在業績會上回應稱不同企業雙抗分子結構存在本質區別，卡度尼利已有三項III期OS陽性結果，不能因單一項目失利否定整個賽道，但市場情緒短期仍偏謹慎，股價在前期累漲後持續回調。</p><p>（以上內容均基於市場公開消息，由程序或算法智能生成，僅作為股價異動提醒，不作為投資建議或交易依據。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>異動解讀｜康方生物盤中下跌3.06%，中期業績不及預期疊加雙抗塌房爭議持續承壓</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n異動解讀｜康方生物盤中下跌3.06%，中期業績不及預期疊加雙抗塌房爭議持續承壓\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1059448697\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">行情直擊 </p>\n<p class=\"h-time smaller\">2026-09-01 09:55</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>9月1日，康方生物盤中下跌3.06%，報87.15港元，成交額2.56億港元，延續上一交易日逾5%的跌勢。</p><p>消息面上，公司此前發布中期業績，上半年總收入18.06億元，按年增長27.92%，期內虧損4.47億元，按年收窄約24%，但仍未實現盈利，收入及毛利不及市場預期。與此同時，阿斯利康PD-1/CTLA-4雙抗臨床失敗引發市場對雙抗賽道的質疑持續發酵。儘管公司董事長夏瑜在業績會上回應稱不同企業雙抗分子結構存在本質區別，卡度尼利已有三項III期OS陽性結果，不能因單一項目失利否定整個賽道，但市場情緒短期仍偏謹慎，股價在前期累漲後持續回調。</p><p>（以上內容均基於市場公開消息，由程序或算法智能生成，僅作為股價異動提醒，不作為投資建議或交易依據。）</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1108327360","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108327360","pubTimestamp":1788227747,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直擊","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"9月1日，康方生物盤中下跌3.06%，報87.15港元，成交額2.56億港元，延續上一交易日逾5%的跌勢。消息面上，公司此前發布中期業績，上半年總收入18.06億元，按年增長27.92%，期內虧損4.47億元，按年收窄約24%，但仍未實現盈利，收入及毛利不及市場預期。與此同時，阿斯利康PD-1/CTLA-4雙抗臨床失敗引發市場對雙抗賽道的質疑持續發酵。（以上內容均基於市場公開消息，由程序或算法智能生成，僅作為股價異動提醒，不作為投資建議或交易依據。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"09926":"康方生物"},"translate_title":"Analysis of Unusual Movements | Akeso Biologics fell 3.06% intraday, with interim results falling short of expectations coupled with continued pressure from the controversy surrounding the collapse of its bispecific antibody product line.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"9月1日，康方生物盤中下跌3.06%，報87.15港元，成交額2.56億港元，延續上一交易日逾5%的跌勢。消息面上，公司此前發布中期業績，上半年總收入18.06億元，按年增長27.92%，期內虧損4.47億元，按年收窄約24%，但仍未實現盈利，收入及毛利不及市場預期。與此同時，阿斯利康PD-1/CTLA-4雙抗臨床失敗引發市場對雙抗賽道的質疑持續發酵。儘管公司董事長夏瑜在業績會上回應稱不同企業雙抗分子結構存在本質區別，卡度尼利已有三項III期OS陽性結果，不能因單一項目失利否定整個賽道，但市場情緒短期仍偏謹慎，股價在前期累漲後持續回調。（以上內容均基於市場公開消息，由程序或算法智能生成，僅作為股價異動提醒，不作為投資建議或交易依據。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}